Additionally, with the expansion of training programs following the Converge PMA approval in April 2021 and easing travel and meeting restrictions, we experienced an increase in associated costs.

Feb 15, 2022 / CFO / receipt, needs a key / Angie Wyrick, CFO | earnings call 2022-02-15 | transcript 1b74351a-48bc-428c-ab44-9f040e203aa2 | chars 14435-14630 | segment 14

The increase resulted mainly from personnel costs, driven by the addition of headcount over last year and variable compensation programs reflecting top-line growth, travel spend returning to normal, and expanding training and market activities as we launch our hybrid AF therapy and continue to drive awareness across our platforms.

Nov 3, 2021 / CFO / receipt, needs a key / Angie Wyrick, CFO | earnings call 2021-11-03 | transcript 7001293d-9395-464a-a74d-b15116b653c9 | chars 10710-11042 | segment 11

The change results mainly from increased variable cash and stock-based compensation offset partially by lower clinical trial expenses reduce travel and discretionary spend for trade shows and internal meetings.

Apr 27, 2021 / CFO / receipt, needs a key / Angie Wyrick, CFO | earnings call 2021-04-27 | transcript 21bf168a-5c2f-47b5-80e5-78d5e8c6d555 | chars 11162-11372 | segment 11